New Dual-Target CAR t therapy takes on Hard-to-Treat myeloma
NCT ID NCT07369895
First seen Jan 31, 2026 · Last updated May 24, 2026 · Updated 22 times
Summary
This early-stage study tests a new treatment called O&D-001 for people with multiple myeloma that has come back or not responded to other therapies. The treatment uses specially engineered immune cells (CAR T cells) that target two proteins, BCMA and GPRC5D, on myeloma cells. The main goals are to check safety and find the right dose, with 18 participants expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.